News
CDTX
0.6770
-4.65%
-0.0330
Cidara Therapeutics Granted U.S. Patent #11510992: Compositions and methods for the treatment of viral infections
Benzinga · 18h ago
BRIEF-Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “For” Proposed Reverse Stock Split
Reuters · 1d ago
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet
Publication details the efficacy and safety of rezafungin dosed once-weekly versus the current of care dosed once-daily Rezafungin PDUFA target action date is scheduled for March 22, 2023 SAN DIEGO and PARSIPPANY, N.J., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ci...
GlobeNewswire · 2d ago
Cidara Therapeutics to Participate in the World Antiviral Congress 2022
SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stei...
GlobeNewswire · 11/23 13:00
Cidara Therapeutics Third Quarter 2022 Earnings: Beats Expectations
Cidara Therapeutics ( NASDAQ:CDTX ) Third Quarter 2022 Results Key Financial Results Revenue: US$40.7m (up 476% from 3Q...
Simply Wall St. · 11/09 10:41
Cidara Therapeutics to Present at the Stifel Healthcare Conference
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey S...
GlobeNewswire · 11/08 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 11/07 12:37
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -43.33% and 8.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 23:05
BRIEF-Cidara Therapeutics Provides Corporate Update And Reports Third Quarter 2022 Financial Results
Reuters · 11/03 22:43
Cidara Therapeutics GAAP EPS of $0.17 beats by $0.10, revenue of $40.74M beats by $18.06M
Seekingalpha · 11/03 21:51
Cidara Therapeutics Q3 EPS $0.17 Up From $(0.37) YoY, Sales $40.74M Up From $7.08M YoY
Benzinga · 11/03 21:49
-- Earnings Flash (CDTX) CIDARA THERAPEUTICS Reports Q3 Revenue $40.7M
-- Earnings Flash (CDTX) CIDARA THERAPEUTICS Reports Q3 Revenue $40.7M
MT Newswires · 11/03 17:54
BRIEF-Cidara Therapeutics To Present New Data For Rezafungin At IDweek 2022
Reuters · 10/17 12:37
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it is pre...
GlobeNewswire · 10/17 12:00
Cidara Therapeutics receives $11.1M milestone payment from Mundipharma
Cidara Therapeutics (NASDAQ:CDTX) has <a href="https://seeking...
Seekingalpha · 10/04 13:24
Cidara spikes on $11M milestone payment from partner Mundipharma
The shares of clinical-stage biotech Cidara Therapeutics (NASDAQ:C...
Seekingalpha · 10/04 12:22
Cidara Therapeutics Receives $11.1M Milestone Payment from Mundipharma; Payment Triggered By European Medicines Agency Acceptance Of Marketing Authorization Application For Rezafungin
Company eligible to receive up to an additional $108M in milestones from multiple existing partnerships based on successful completion of activities planned for the next two years SAN DIEGO, Oct. 04, 2022
Benzinga · 10/04 12:01
Cidara Therapeutics Gets $11 Million Milestone Payment From Mundipharma
Cidara Therapeutics Gets $11 Million Milestone Payment From Mundipharma
MT Newswires · 10/04 11:05
Cidara's Lead Antifungal Candidate Goes Under Priority FDA Review
Benzinga · 09/21 14:27
More
Webull provides a variety of real-time CDTX stock news. You can receive the latest news about Cidara Theraptcs through multiple platforms. This information may help you make smarter investment decisions.
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The Company's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.